KD Logo

RBC Capital Mkts Upgrades Sarepta Therapeutics Inc (SRPT) to an Outperform from a Sector perform

Sarepta Therapeutics Inc’s recently made public that its Chief Financial Officer Estepan Ian Michael unloaded Company’s shares for reported $0.82 million on Aug 30 ’24. In the deal valued at $137.36 per share,5,985 shares were sold. As a result of this transaction, Estepan Ian Michael now holds 33,946 shares worth roughly $4.09 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Estepan Ian Michael bought 5,985 shares, generating $822,130 in total proceeds.

Before that, Chambers Michael Andrew bought 37,038 shares. Sarepta Therapeutics Inc shares valued at $4,955,728 were divested by the Director at a price of $133.80 per share. As a result of the transaction, Chambers Michael Andrew now holds 284,034 shares, worth roughly $34.2 million.

RBC Capital Mkts upgraded its Sarepta Therapeutics Inc [SRPT] rating to an Outperform from a a Sector perform in a research note published recently. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in late June from “a Buy” to “a Neutral”. Piper Sandler began covering SRPT with “an Overweight” recommendation on May 31, 2024. RBC Capital Mkts revised its rating on May 28, 2024. It rated SRPT as “a Sector perform” which previously was an “an Outperform”.

Price Performance Review of SRPT

On Friday, Sarepta Therapeutics Inc [NASDAQ:SRPT] saw its stock jump 1.38% to $120.40. Over the last five days, the stock has lost -3.32%. Sarepta Therapeutics Inc shares have risen nearly 24.86% since the year began. Nevertheless, the stocks have risen 2.20% over the past one year. While a 52-week high of $173.25 was reached on 06/21/24, a 52-week low of $55.25 was recorded on 01/05/24. SMA at 50 days reached $132.70, while 200 days put it at $128.28.

Levels Of Support And Resistance For SRPT Stock

The 24-hour chart illustrates a support level at 118.73, which if violated will result in even more drops to 117.05. On the upside, there is a resistance level at 121.98. A further resistance level may holdings at 123.55. The Relative Strength Index (RSI) on the 14-day chart is 32.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.60, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.17%. Stochastics %K at 18.09% indicates the stock is a buying.

How much short interest is there in Sarepta Therapeutics Inc?

A steep rise in short interest was recorded in Sarepta Therapeutics Inc stocks on 2024-09-13, dropping by -0.58 million shares to a total of 6.15 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 6.73 million shares. There was a decline of -9.5%, which implies that there is a negative sentiment for the stock.

Most Popular